Facebook Facebook Share

As part of our policy and campaigns work Target Ovarian Cancer regularly produces reports which cover issues including awareness of the symptoms of ovarian cancer and women’s experience of treatment.

We also respond to consultations from public bodies, including the government, the NHS, and bodies responsible for clinical guidelines in relation to ovarian cancer or access to new drugs and treatments. When a public body plans to change an existing, or introduce a new, policy or set of guidelines, then it runs a public consultation. Our responses reflect the priorities of women with ovarian cancer and the changes needed to improve diagnosis and treatment.

Reports

APPG on Ovarian Cancer Diagnosing ovarian cancer sooner: what more can be doneDiagnosing ovarian cancer sooner: what more can be done 

The first report from the All-Party Parliamentary Group (APPG) on Ovarian Cancer shares the findings of its inquiry into early diagnosis. Alongside written evidence submissions, two oral evidence sessions heard from expert witnesses including Professor Chris Harrison, National Clinical Director for Cancer, NHS England, and Professor Anne Mackie, Director of Screening, Public Health England. The report calls for more to be done to raise awareness of the symptoms of ovarian cancer and for full roll-out of the cancer strategy as it relates to ovarian cancer.

Read the report

 

PathfindPathfinder Englander England

Pathfinder England is our first report focusing exclusively on England. It looks at awareness of the symptoms of ovarian cancer, GP knowledge of the disease and women's experience of diagnosis and treatment.

Read the report

 

 

Pathfinder Northern IrelandPathfinder Northern Ireland

Pathfinder Northern Ireland is our first report focusing exclusively on Northern Ireland. It looks at awareness of the symptoms of ovarian cancer, GP knowledge of the disease and women's experience of diagnosis and treatment.

Read the report

 

 

Pathfinder WalesPathfinder CymruPathfinder Wales/Pathfinder Cymru

Pathfinder Wales/Pathfinder Cymru is our first report focusing exclusively on Wales. It looks at awareness of the symptoms of ovarian cancer, GP knowledge of the disease and women's experience of diagnosis and treatment.

Read the report

 

 

Pathfinder ScotlandPathfinder Scotland

Pathfinder Scotland is our first report focusing exclusively on Scotland. It looks at awareness of the symptoms of ovarian cancer, GP knowledge of the disease and women's experience of diagnosis and treatment.

Read the report

 

 

 

Regional variation in the diagnosis of ovarian cancer in EnglandRegional variation in the diagnosis of ovarian cancer

The first report from our GP Advisory Board looks at differences in the numbers of CA125 blood tests ordered, the time taken to complete non-obstetric ultrasounds, stage at diagnosis and one year survival rates for different parts of England. It calls for work to shorten the diagnostic pathway and improvements in how data is collected and used so all parts of the country can match the best performing areas.

Read the report

 

 

 

Pathfinder 2016Pathfinder 2016

Pathfinder is Target Ovarian Cancer’s groundbreaking research that provides a detailed picture of the experiences of people living and working with ovarian cancer in the UK. Pathfinder 2016 is our third UK wide report and is based on surveys of women in the general population, GPs, women with ovarian cancer, Clinical Nurse Specialists and family and friends. It shows where progress has been made but also where more remains to be done. It makes a series of recommendations including investment in national public awareness campaigns to ensure more women know the symptoms to look out for and a clinical audit to map diagnosis and treatment of ovarian cancer and identify areas for improvement.

Read the report

 

The Ovarian Cancer Postcode lotteryThe Ovarian Cancer Postcode Lottery

While cancer doesn’t discriminate according to postcode, Target Ovarian Cancer research has found that women’s awareness of the symptoms, access to clinical trials and likelihood of surviving ovarian cancer can vary hugely according to where they live.

Read the report

 

PatPathfinder 2012hfinder 2012

Pathfinder is Target Ovarian Cancer’s groundbreaking research that provides a detailed picture of the experiences of people living and working with ovarian cancer in the UK. Our second Pathfinder report highlighted delays in diagnosis, issues accessing Clinical Nurse Specialists and a fall in the number of women with ovarian cancer being offered access to clinical trials. In response we invested in GP training, launched our award-winning Ovarian Cancer Clinical Trials Information Centre and successfully campaigned for government funded awareness pilots for ovarian cancer.

Read the report

 

 

Pathfinder 2009Pathfinder 2009

Pathfinder is Target Ovarian Cancer’s groundbreaking research that provides a detailed picture of the experiences of people living and working with ovarian cancer in the UK. Our first ever Pathfinder study demonstrated that many women face delays in getting a diagnosis and that GPs lacked direct access to diagnostic tests; this led to a government commitment to investment in ultrasound.

Read the report

 

 

Consultation responses

National Institute for Health and Care Excellence appraisal of niraparib

The National Institute for Health and Care Excellence (NICE) is currently considering whether new cancer drug niraparib (Zejula®) can be funded on the NHS. Target Ovarian Cancer responded to the initial consultation which was focused on the need for new treatments for ovarian cancer. We then gave evidence at the NICE Committee meeting considering niraparib and responded to a further more detailed consultation on funding for niraparib. NICE has said it will publish its final decision in June.

Read our response to NICE’s initial consultation for niraparib – September 2017

Niraparib - Patient carer organisation submission - Target Ovarian Cancer

Read the Appraisal Consultation Document (ACD) – February 2018

Niraparib - Appraisal Consultation Document

Read our response to the ACD – February 2018

Niraparib - ACD stakeholder comments - Target Ovarian Cancer

Proposed changes to how the National Institute for Health and Care Excellence (NICE) evaluates and funds new drugs - October 2016 – January 2017

NHS England and NICE consulted on changes to how new drugs are evaluated and funded, including a proposal for a further process for any new drug expected to cost the NHS £20 million a year or more.

Read the consultation document

Proposals for changes to how NICE evaluates and funds new drugs

Read our response

Proposals for changes to NICE evaluations - a response from Target Ovarian Cancer - January 2017

Proposed changes to Clinical Reference Groups (CRGs) - February 2016 – March 2016

CRGs are responsible for setting the standards to which services for more specialised care, including for ovarian cancer, are commissioned. This consultation looked at how they are structured.

Read the consultation document

Proposed revisions to Clinical Reference Groups

Read our response

Proposed revisions to Clinical Reference Groups - a response from Target Ovarian Cancer - March 2016

Changes to the Cancer Drugs Fund - November 2015 – February 2016

NHS England and National Institute for Health and Care Excellence consultation on changes to the Cancer Drugs Fund.

Read the consultation document

Consultation on proposals for a new Cancer Drugs Fund

Read our response

Consultation on proposals for a new Cancer Drugs Fund - a response from Target Ovarian Cancer - February 2016

Genetic testing for BRCA1 and BRCA2 mutations - March 2015 – April 2015

Following new guidelines in 2013 which recommended that all women with non-mucinous ovarian cancer be offered genetic, NHS England consulted on how this should be commissioned.

Read the consultation document

Clinical Commissioning Policy on genetic testing for BRCA1 and BRCA2 mutations

Read our response

Draft Clinical Commissioning Policy - genetic testing for BRCA1 and BRCA2 mutations - a response from Target Ovarian Cancer - April 2015

Call for evidence for new cancer strategy for England - November 2014 – February 2015

The Government asked Sir Harpal Kumar, Chief Executive of Cancer Research UK, to lead an independent taskforce to develop a new five year cancer strategy for England.

Read our response

Cancer strategy taskforce - a response from Target Ovarian Cancer - February 2015